(NASDAQ: MRKR) Marker Therapeutics's forecast annual revenue growth rate of 188.44% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 78.36%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Marker Therapeutics's revenue in 2025 is $5,388,071.On average, 1 Wall Street analysts forecast MRKR's revenue for 2025 to be $15,526,692, with the lowest MRKR revenue forecast at $15,526,692, and the highest MRKR revenue forecast at $15,526,692. On average, 1 Wall Street analysts forecast MRKR's revenue for 2027 to be $297,594,930, with the lowest MRKR revenue forecast at $297,594,930, and the highest MRKR revenue forecast at $297,594,930.
In 2028, MRKR is forecast to generate $1,891,668,642 in revenue, with the lowest revenue forecast at $1,891,668,642 and the highest revenue forecast at $1,891,668,642.